Combined Flow Cytometry and Morphology Review
Biopharma: This test is available for use in clinical trials or research purposes only.
Expected Turnaround Time
5 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
Combined Immunophenotyping for myeloid / lymphoid markers with H&E morphology review.
Requisition Forms
Specimen Requirements
Specimen Requirements
- Whole Blood: 4 mL (minimum of 0.5 mL with 107 cells), NaHep preferred (EDTA accepted)
- Bone Marrow Aspirate: 2 mL (minimum of 0.5 mL with 107 cells), NaHep preferred (EDTA accepted)
- Bone Marrow Core Biopsy: 2 cm (minimum of 1 cm), Sterile container with 2-4 mL RPMI transport media or sterile saline
- Fresh Tissue: 5 mm3, Sterile container with 2-4 mL RPMI transport media or sterile saline
Specimen Stability
Specimen stable for 48 hours at 4°C.
Storage Requirements
2°C to 8°C
Shipping Conditions
Refrigerated
Shipping Recommendations
REFRIGERATED, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen
Specimen Rejection Criteria
Specimens stored at incorrect temperature; Non-viable specimens; Specimens in inappropriate anticoagulant; Too few cells; Hemolysis; Specimen clotted
Test Details
Keywords
Pathology,Flow Cytometry,Leukemia,Oncology,Acute Lymphoblastic Leukemia (ALL),Acute Myeloid Leukemia (AML),Chronic Myelogenous Leukemia (CML),Hypereosinophilia / Mast Cell,Chronic Lymphocytic Leukemia (CLL),Lymphoma,Myelodysplastic Syndrome (MDS),Myelopro, flow,leukemia,immunophenotyping,myeloid,lymphoid,non-hodgkin lymphoma,cytometry
Test Method
Flow cytometry
Methodology Category
Flow Cytometry
Associations
Acute myeloid leukemia, Acute lymphoblastic leukemia, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma